COMMUNIQUÉS West-GlobeNewswire

Bioxodes receives European Patent Office intention to grant patent, offering lead asset broad protection in thromboinflammation
16/05/2024
Gosselies (Belgium), May 16, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, announces today it has [...]
L'Office européen des brevets notifie Bioxodes de son intention de délivrer un brevet offrant une large protection à son actif principal dans le traitement des thrombo-inflammations
16/05/2024
Gosselies (Belgique), le 16 mai 2024 – Bioxodes SA, société biopharmaceutique de stade clinique développant de nouvelles thérapies dédiées à la prévention et au traitement de maladies thrombotiques et inflammatoires, [...]
LIfT BioSciences Awarded Innovate UK Grant to Accelerate Product Development of New IMAN Cell Therapy Variants
16/05/2024
LIfT BioSciences Awarded Innovate UK Grant to Accelerate Product Development of New IMAN Cell Therapy Variants Groundbreaking in vivo studies will be progressed to explore the impact of IMAN cell therapies in solid [...]
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
16/05/2024
Allschwil, Switzerland, May 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections [...]
Zealand Pharma Announces Financial Results for the First Quarter of 2024
16/05/2024
Company announcement - No. 26 / 2024 Zealand Pharma Announces Financial Results for the First Quarter of 2024 Strong performance in the first quarter of 2024 paving the way for important data read-outs across [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
16/05/2024
Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001) At week 24, 100% of CT-388 treated [...]
HEPHAISTOS secures €10.3 M to reach the clinical stage
16/05/2024
PR: HEPHAISTOS secures €10.3 M to reach the clinical stage HEPHAISTOS-Pharma welcomes Elaia to complete its Seed Round, securing a total of €10.3 million from investors and non-dilutive financing. €4.5M seed round led [...]
HEPHAISTOS sécurise 10,3 M€ pour aller jusqu’en clinique
16/05/2024
Communiqué : HEPHAISTOS sécurise 10,3 M€ pour aller jusqu’en clinique HEPHAISTOS-Pharma accueille Elaia qui boucle son tour d’amorçage, sécurisant ainsi un total de 10,3 millions d'euros, entre financements dilutifs et [...]
CloudMD Reports 2023 Results for the Full Year and Fourth Quarter
16/05/2024
Full year 2023 revenue of $90.9 million compared to $99.4 million in 2022, and $90.5 million compared to $86.7 million on a normalized basis, excluding one-time COVID mandates. Q4 2023 gross profit margin 1 of 39.7% was [...]
Assure & Danam Postpone Corporate Update Call & Webcast Scheduled for May 16
16/05/2024
DENVER, May 15, 2024 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, announced today that the [...]
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
16/05/2024
Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage [...]
ONWARD® Medical organise un webinaire pour présenter l’état des lieux de ses activités du premier trimestre 2024
16/05/2024
EINDHOVEN, Pays-Bas, 16 mai 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), société de technologie médicale à l’origine de thérapies innovantes ciblées sur la restauration du mouvement, de la fonction et [...]
DiagnaMed Announces LIFE Offering of up to $650,000
16/05/2024
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is pleased to announce that [...]
Spectral AI Announces Voting Results from 2024 Annual Meeting of Stockholders and the Appointment of Erich Spangenberg to the Board of Directors
16/05/2024
DALLAS, May 15, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
16/05/2024
Last patient last visit in randomized, double-blind, SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease is scheduled for early June 2024 ROCHESTER, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, [...]
CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
15/05/2024
Reported Full Year 2023 total revenues of 2% growth at €48.5 million Secured approximately USD 20 million – strengthening cash position and expanding relationship with Lifera, a biopharma company owned by the PIF [...]
Range Impact Reports 1Q 2024 Financial Results
15/05/2024
CLEVELAND, OHIO, May 15, 2024 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact”), a public impact investing company dedicated to acquiring, reclaiming and repurposing mine sites in Appalachia, reported [...]
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
15/05/2024
Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated Topline results [...]
Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update
15/05/2024
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of [...]

Pages